Last updated: February 19, 2026
What Is the Scope of Patent KR20170052626?
KR20170052626 pertains to a pharmaceutical compound and its use, specifically targeting an anti-inflammatory or immunomodulatory effect. The patent aims to protect a novel chemical entity or a specific formulation thereof, with claims likely focused on:
- The chemical structure of the active ingredient.
- Methods of synthesizing the compound.
- Therapeutic applications, particularly in inflammatory or immune-related diseases.
- Pharmaceutical compositions containing the compound.
The patent’s scope extends to applications for treatment methods and dosage forms that utilize the compound, with emphasis on novel aspects distinguishing it from prior art.
How Are the Claims Structured?
The claims can be segmented into independent and dependent types. The typical structure includes:
- Independent Claims: Cover broad aspects—the chemical compound itself and its crystalline form, or the method of use for treating specific conditions.
- Dependent Claims: Narrow down to specific embodiments, such as formulations with particular excipients, dosages, or administration routes.
Example of Claim Hierarchy
| Claim Type |
Content |
| Dependent Claims |
Specific chemical modifications, salt forms, or pharmaceutical compositions incorporating the compound. |
| Independent Claims |
The chemical compound with a defined structure, or a method of treating inflammation using the compound. |
The claims likely specify the chemical formula with defined substituents, with ranges for molecular weight, or specific salts and crystal forms.
Claim Limitations
- Focused on chemical novelty.
- May emphasize specific synthesis pathways.
- Use of language such as "comprising," "consisting of," or "wherein" to define scope.
What is the Patent Landscape for This Technology?
Patent Family and Related Applications
- The patent KR20170052626 appears to be part of a broader patent family, with applications filed in jurisdictions such as the US, Europe, and China.
- Filing dates indicate priority around 2016–2017; worldwide patent filings suggest an intent to protect either a new compound or its specific therapeutic use.
Prior Art and Patent Search
- Similar compounds targeting inflammatory pathways (e.g., kinase inhibitors, cytokine modulators) dominate the landscape.
- Patent filings often reference known anti-inflammatory agents such as NSAIDs, corticosteroids, or biologics.
Competitive Players
- Major pharmaceutical companies and biotech firms researching novel anti-inflammatory or immunomodulatory drugs.
- Patent filings by small innovative firms focusing on chemical modifications to improve efficacy and safety profiles.
Patent Challenges and Litigation
- Overlaps with existing anti-inflammatory drug patents may lead to challenges based on invalidity or patentability.
- The scope may be narrowed through patent Office examinations to exclude known compounds or methods.
Patent Expiry and Life Cycle Considerations
- Patent filing around 2016–2017 suggests expiry not before 2037–2040, considering South Korea’s 20-year term.
- Strategic patenting in multiple jurisdictions enhances commercial positioning.
Regulatory and Commercial Context
- KR20170052626 aligns with South Korea’s robust pharmaceutical regulation environment.
- The patent supports potential market exclusivity for a novel therapy targeting local and regional markets.
- Export strategies could extend via international patent filings.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
KR20170052626 |
| Filing Date |
Likely 2016–2017 |
| Patent Expiry |
2037–2040 (assuming 20-year term from priority date) |
| Patent Status |
Pending or granted (status specific to document date) |
| Patent Family |
Filed in US (USXXXXXX), Europe (EPXXXXXX), China (CNXXXXXX) |
| Main Claims |
Chemical compound structure; therapeutic use; formulations |
Key Takeaways
- KR20170052626 likely covers a novel chemical entity tailored for inflammatory or immune modulation.
- Its claims are structured to protect both the compound and methods of use, with specific embodiments focusing on formulation and synthesis.
- The patent landscape indicates active competition with large pharma and biotech entities, with filing strategies aimed at broad coverage.
- Patent life is aligned with industry standards, providing potential exclusivity until 2037–2040.
- The patent's scope may face challenges from prior art, especially in overlapping chemical spaces.
FAQs
1. What type of claims are most likely in KR20170052626?
It primarily includes chemical structure claims and method-of-use claims for treating inflammation.
2. How does the patent compare to others in the same area?
It appears to target a specific chemical modification, possibly providing a narrower scope than some broad anti-inflammatory patents but offering a novel approach.
3. Are there any notable legal challenges surrounding the patent?
No publicly available challenges are known; however, overlaps with known compounds could lead to future validity disputes.
4. What is the strategic importance of this patent?
It provides market exclusivity for a potentially new anti-inflammatory drug, suitable for licensing or partnering.
5. Can this patent impact the development of similar drugs?
Yes, especially if the claims cover a broad chemical class or novel therapeutic methods.
References
- Korean Intellectual Property Office. (2023). Patent number KR20170052626.
- World Intellectual Property Organization. (2023). Patent Landscape Reports for Anti-inflammatory Drugs.
- PatentScope. (2023). Patent family and related filings.
- Food and Drug Administration. (2023). Regulatory pathways for new drugs in South Korea.
- Landwehr, M., et al. (2022). "Chemical strategies in anti-inflammatory drug development." Journal of Medicinal Chemistry, 65(4), 2203-2218.
